Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
PLX 
Protalix Biotherapeutics Inc (PLX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
11/17/2025: PLX (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $12.5
1 Year Target Price $12.5
| 0 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 23.43% | Avg. Invested days 25 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 11/17/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 152.00M USD | Price to earnings Ratio 23.62 | 1Y Target Price 12.5 |
Price to earnings Ratio 23.62 | 1Y Target Price 12.5 | ||
Volume (30-day avg) 1 | Beta -0.27 | 52 Weeks Range 1.32 - 3.10 | Updated Date 11/17/2025 |
52 Weeks Range 1.32 - 3.10 | Updated Date 11/17/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 0.08 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date 2025-11-13 | When - | Estimate 0.07 | Actual 0.03 |
Profitability
Profit Margin 8.72% | Operating Margin (TTM) 11.94% |
Management Effectiveness
Return on Assets (TTM) 5.53% | Return on Equity (TTM) 12.64% |
Valuation
Trailing PE 23.62 | Forward PE 3.41 | Enterprise Value 130803032 | Price to Sales(TTM) 2.46 |
Enterprise Value 130803032 | Price to Sales(TTM) 2.46 | ||
Enterprise Value to Revenue 1.96 | Enterprise Value to EBITDA 11.7 | Shares Outstanding 80421181 | Shares Floating 61408005 |
Shares Outstanding 80421181 | Shares Floating 61408005 | ||
Percent Insiders 10.15 | Percent Institutions 17.55 |
Upturn AI SWOT
Protalix Biotherapeutics Inc
Company Overview
History and Background
Protalix Biotherapeutics Inc. was founded in 1993 and is an Israeli biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins produced through its plant cell-based protein expression system, ProCellEx. It has achieved milestones with FDA approvals for its products.
Core Business Areas
- Rare Diseases: Develops and commercializes therapeutics for rare genetic diseases, primarily focused on enzyme replacement therapies.
Leadership and Structure
The leadership team consists of experienced executives in the pharmaceutical industry. The organizational structure is typical of a biopharmaceutical company, with departments focused on research and development, clinical trials, manufacturing, and commercial operations.
Top Products and Market Share
Key Offerings
- Elelyso (taliglucerase alfa): Elelyso is an enzyme replacement therapy (ERT) for Gaucher disease. It competes with Sanofi's Cerezyme and Takeda's Vpriv. GlobalData estimates the Gaucher disease treatment market to reach $2.1 billion by 2029. Elelyso's market share is smaller compared to the market leaders.
Market Dynamics
Industry Overview
The biopharmaceutical industry, specifically the enzyme replacement therapy (ERT) market for rare diseases, is competitive. Key drivers include increasing diagnosis rates, orphan drug designations, and advancements in protein engineering.
Positioning
Protalix is positioned as a company focusing on plant cell-based protein expression, offering potential advantages in terms of manufacturing scalability and cost. Its competitive advantage lies in its proprietary ProCellEx platform.
Total Addressable Market (TAM)
The total addressable market for Gaucher disease and related rare diseases is estimated in the billions of dollars. Protalix aims to expand its reach within this TAM through new product development and strategic partnerships.
Upturn SWOT Analysis
Strengths
- Proprietary ProCellEx platform
- Approved product (Elelyso)
- Focus on rare diseases
- Partnerships with major pharmaceutical companies
Weaknesses
- Reliance on a limited product portfolio
- Smaller market share compared to larger competitors
- Dependence on partnerships for commercialization
- History of financial losses
Opportunities
- Expanding Elelyso's market reach
- Developing new products based on ProCellEx
- Securing additional partnerships
- Acquiring complementary technologies or companies
Threats
- Competition from established ERT products
- Biosimilar competition
- Regulatory hurdles
- Clinical trial failures
- Economic downturn impacting healthcare spending
Competitors and Market Share
Key Competitors
- SNY
- TAK
Competitive Landscape
Protalix's advantages lie in its ProCellEx platform. Disadvantages include smaller scale and market reach compared to competitors.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been driven by Elelyso sales and partnerships. Growth has been slow.
Future Projections: Future growth is dependent on the success of pipeline products and strategic partnerships. Analyst estimates vary.
Recent Initiatives: Recent initiatives include advancing clinical trials for new product candidates and expanding partnerships.
Summary
Protalix Biotherapeutics is a biopharmaceutical company with a proprietary plant cell-based protein expression platform. It has one FDA-approved product, Elelyso, for Gaucher disease, but faces significant competition. Future growth depends on the success of its pipeline and partnerships. The company needs to focus on expanding its market share and diversifying its product portfolio.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Analyst Reports
Disclaimers:
The data provided is for informational purposes only and should not be considered investment advice. Market share data is estimated and may vary.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Protalix Biotherapeutics Inc
Exchange NYSE MKT | Headquaters Hackensack, NJ, United States | ||
IPO Launch date 1998-05-15 | President, CEO & Director Mr. Dror Bashan | ||
Sector Healthcare | Industry Biotechnology | Full time employees 213 | Website https://www.protalix.com |
Full time employees 213 | Website https://www.protalix.com | ||
Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on the ProCellEx plant cell-based protein expression system. The company offers Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell expressed recombinant PEGylated Uricase, which is in Phase 2 trial for the treatment of gout; and PRX-119, a plant cell expressed PEGylated recombinant human DNase I product candidate for the treatment of neutrophil extracellular traps diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A. It operates in the United States, Australia, Canada, Israel, Brazil, Russia, and Turkey. The company is headquartered in Hackensack. New Jersey.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.